BMI as Factor Predicting the Efficacy of Gefitinib in NSCLC with EGFR Mutation

被引：0
|
作者：
Sun Hongyan [1 ]
Sun Xiaoteng [2 ]
Zhai Xiaoyu [3 ,4 ]
Guo Jingfeng [5 ]
Liu Yutao [3 ,4 ]
Ying Jianming [4 ,6 ]
Wang Ziping [3 ,4 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Ling Nan Hosp, Gen Internal Dept, Guangzhou 510275, Guangdong, Peoples R China
[2] Rushan Cty PeopleS Hosp, Dept Pathol, Weihai, Shandong, Peoples R China
[3] Chinese Acad Med Sci, Dept Med Oncol, Canc Inst Hosp, Beijing 100730, Peoples R China
[4] Peking Union Med Coll, Beijing 100021, Peoples R China
[5] Southern Med Univ, Hexian Affiliated Mem Hosp, Guangzhou, Guangdong, Peoples R China
[6] Chinese Acad Med Sci, Dept Pathol, Canc Inst Hosp, Beijing 100730, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
classification and regression tree (CART); non-small-cell lung cancer (NSCLC); EGFR active mutation; body mass index (BMI);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-022
引用
收藏
页码：S528 / S529
页数：2
相关论文
共 50 条
  • [1] COMPARISON OF THE EFFICACY OF GEFITINIB IN PATIENTS WITH NSCLC ACCORDING TO THE TYPE OF EGFR MUTATION
    Kasajima, Masashi
    Igawa, Satoshi
    Ishihara, Mikiko
    Kimura, Michiko
    Kusuhara, Seiichiro
    Harada, Sinya
    Hiyoshi, Yasuhiro
    Katono, Ken
    Sasaki, Jiichiro
    Masuda, Noriyuki
    ANNALS OF ONCOLOGY, 2014, 25
  • [2] EGFR copy number and gefitinib efficacy in advanced NSCLC
    Nature Clinical Practice Oncology, 2005, 2 (7): : 328 - 328
  • [3] Clinical research on the efficacy of self-made sichongsan in combination with gefitinib on NSCLC patients with EGFR mutation
    Zhao, Yibo
    Dong, Yu
    Xing, Shu
    Fu, Xueqi
    EUROPEAN JOURNAL OF INFLAMMATION, 2018, 16 : 1 - 4
  • [4] Therapeutic effect of gefitinib on patients with advanced EGFR-mutation NSCLC
    Xu, Ailing
    Yan, Haixia
    Bu, Tongliang
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 34 (01) : 481 - 486
  • [5] P53 Disruptive Mutation Is a Negative Predictive Factor in EGFR M plus NSCLC Treated with TKIEfficacy and Safety of Gefitinib for Elderly Patients with EGFR Mutation Positive NSCLC
    Kusaka, Kei
    Hirose, Takashi
    Tamura, Atsuhisa
    Ide, Satoshi
    Saito, Minako
    Ogiya, Masahiro
    Inoue, Eri
    Tashimo, Hiroyuki
    Yamane, Akira
    Matsui, Hirotoshi
    Ohta, Ken
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S647 - S648
  • [6] COMPARISON OF THE EFFICACY BETWEEN CHEMOTHERAPY AND GEFITINIB AS 1ST LINE SETTING IN PATIENTS WITH EGFR MUTATION POSITIVE NSCLC
    Yoshida, K.
    Okamoto, I.
    Kobayashi, K.
    Sunaga, N.
    Sugio, K.
    Inoue, A.
    Yamazaki, K.
    Morita, S.
    Nukiwa, T.
    Fukuoka, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 104 - 104
  • [7] FIRST LINE GEFITINIB IN EGFR MUTATION POSITIVE NSCLC IN AN ISRAELI COHORT: UNMET EXPECTATIONS
    Urban, Damien
    Maimon-Rabinovich, Natalie
    Mishaeli, Moshe
    Leibowitz-Amit, Raya
    Biran, Haim
    Onn, Amir
    Gottfried, Maya
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1189 - S1190
  • [8] THERAPEUTIC EFFICACY OF GEFITINIB FOR POSTOPERATIVE RECURRENT CANCER IN PATIENT WITH EGFR MUTATION
    Oikawa, Takefumi
    Ohira, Tatsuo
    Osawa, Junichiro
    Hagiwara, Masaru
    Kakihana, Masatoshi
    Kajiwara, Naohiro
    Ikeda, Norihiko
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S884 - S884
  • [9] Efficacy of gefitinib combined with bevacizumab versus gefitinib in advanced EGFR L858R NSCLC.
    Zhao, Xinmin
    Wu, Xianghua
    Wang, Huijie
    Yu, Hui
    Sun, Si
    Feng, Yu
    Wang, Jialei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Gefitinib Approved for EGFR-Mutated NSCLC
    不详
    CANCER DISCOVERY, 2015, 5 (09) : 896 - 896
12345